<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

5 min read

Q120 Trauma Market Growth Halted Mid-March by COVID-19 Pandemic

6/25/20 9:30 AM

Q120 Trauma HeaderCOVID-19 halts the Trauma Market’s Q120 growth, leading to a -2.8% YoY decline globally.

Q120 was tracking as a stable quarter for the US Trauma Market, following Q419’s +3.8% growth, however, this was interrupted in mid-March by the COVID-19 pandemic. The US Trauma Market was down -1.2% YoY for the quarter, with WW revenues declining -2.8%. The non-elective trauma market experienced a reduction in trauma admissions due to the decrease in daily activities and limited driving for most of the US.

Among the many topics covered in the comprehensive Q120 Trauma Market Recap* are:

  • Complete Trauma Market Highlights
  • Slowdown in Urgent Trauma Procedures
  • Top Players Derailed by COVID-19 Pandemic in Q120
  • Q120 Trauma Regulatory Highlights

As a result of COVID-19 and the stay-at-home orders trauma surgeons reported seeing definite decreases in volumes, with polytrauma being almost negligible in certain cities, according to an OTA COVID-19 Webinar discussion held late March. Geriatric fractures seem to have decreased but to a lesser extent according to the OTA COVID-19 Webinar discussion.

While stay-at-home orders certainly caused a decrease in daily activity that impacted trauma volumes, SmartTRAK believes most trauma fracture fixation procedures presented at facilities were treated. Based on surgeon feedback, only a small portion received conservative treatment if a facility or area was heavily impacted by COVID-19 and ...

Read the entire Q120 Trauma Market Recap including news, data, charts, company revenues and analysis*

*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.

Learn More

Topics: Orthopedics

Natasha Weeks
Written by Natasha Weeks

13 years' experience in marketing and product development, including 5+ years at DePuy Synthes Trauma - most recently as Product Director at DePuy Synthes Trauma.

    Recent Articles